
PMC:7543452
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 68-76 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T2 | 77-85 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T3 | 128-152 | Disease | denotes | Coronavirus Disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 154-162 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 174-183 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T6 | 444-454 | Disease | denotes | infectious | http://purl.obolibrary.org/obo/MONDO_0005550 |
T7 | 789-797 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T8 | 1436-1444 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T9 | 1493-1501 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 167-168 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T2 | 202-203 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T3 | 305-313 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T4 | 423-424 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T5 | 572-573 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T6 | 623-624 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T7 | 907-908 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T8 | 1025-1033 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T9 | 1101-1102 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T10 | 1264-1265 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 39-49 | Chemical | denotes | antivirals | http://purl.obolibrary.org/obo/CHEBI_22587 |
T2 | 295-304 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T3 | 922-928 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T4 | 1054-1064 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T5 | 1359-1377 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T6 | 1381-1400 | Chemical | denotes | lopinavir-ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T7 | 1381-1390 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T8 | 1391-1400 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T9 | 1411-1430 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
T11 | 1420-1430 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T12 | 1681-1691 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
2 | 54-62 | Species | denotes | children | Tax:9606 |
3 | 68-76 | Disease | denotes | COVID-19 | MESH:C000657245 |
9 | 192-200 | Species | denotes | children | Tax:9606 |
10 | 404-412 | Species | denotes | children | Tax:9606 |
11 | 128-152 | Disease | denotes | Coronavirus Disease 2019 | MESH:C000657245 |
12 | 154-162 | Disease | denotes | COVID-19 | MESH:C000657245 |
13 | 174-183 | Disease | denotes | infection | MESH:D007239 |
15 | 444-463 | Disease | denotes | infectious diseases | MESH:D003141 |
29 | 801-809 | Species | denotes | children | Tax:9606 |
30 | 866-874 | Species | denotes | children | Tax:9606 |
31 | 1188-1196 | Species | denotes | children | Tax:9606 |
32 | 1309-1317 | Species | denotes | patients | Tax:9606 |
33 | 1448-1456 | Species | denotes | children | Tax:9606 |
34 | 922-928 | Chemical | denotes | oxygen | MESH:D010100 |
35 | 1054-1064 | Chemical | denotes | remdesivir | MESH:C000606551 |
36 | 1132-1142 | Chemical | denotes | Remdesivir | MESH:C000606551 |
37 | 1359-1377 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
38 | 1381-1400 | Chemical | denotes | lopinavir-ritonavir | MESH:C558899 |
39 | 789-797 | Disease | denotes | COVID-19 | MESH:C000657245 |
40 | 1173-1187 | Disease | denotes | critically ill | MESH:D016638 |
41 | 1436-1444 | Disease | denotes | COVID-19 | MESH:C000657245 |
46 | 1555-1563 | Species | denotes | patients | Tax:9606 |
47 | 1569-1577 | Species | denotes | children | Tax:9606 |
48 | 1681-1691 | Chemical | denotes | remdesivir | MESH:C000606551 |
49 | 1493-1501 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-87 | Sentence | denotes | Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2 |
T2 | 89-97 | Sentence | denotes | Abstract |
T3 | 98-106 | Sentence | denotes | Abstract |
T4 | 108-118 | Sentence | denotes | Background |
T5 | 119-256 | Sentence | denotes | Although Coronavirus Disease 2019 (COVID-19) is a mild infection in most children, a small proportion develop severe or critical illness. |
T6 | 257-413 | Sentence | denotes | Data evaluating agents with potential antiviral activity continue to expand, such that updated guidance is needed regarding use of these agents in children. |
T7 | 415-422 | Sentence | denotes | Methods |
T8 | 423-563 | Sentence | denotes | A panel of pediatric infectious diseases physicians and pharmacists from 20 geographically diverse North American institutions was convened. |
T9 | 564-744 | Sentence | denotes | Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of the best available evidence and expert opinion. |
T10 | 746-753 | Sentence | denotes | Results |
T11 | 754-861 | Sentence | denotes | Given the typically mild course of COVID-19 in children, supportive care alone is suggested for most cases. |
T12 | 862-1131 | Sentence | denotes | For children with severe illness, defined as a supplemental oxygen requirement without need for non-invasive or invasive mechanical ventilation or extra-corporeal membrane oxygenation (ECMO), remdesivir is suggested, preferably as part of a clinical trial if available. |
T13 | 1132-1263 | Sentence | denotes | Remdesivir should also be considered for critically ill children requiring invasive or non-invasive mechanical ventilation or ECMO. |
T14 | 1264-1318 | Sentence | denotes | A duration of 5 days is appropriate for most patients. |
T15 | 1319-1457 | Sentence | denotes | The panel recommends against the use of hydroxychloroquine or lopinavir-ritonavir (or other protease inhibitors) for COVID-19 in children. |
T16 | 1459-1470 | Sentence | denotes | Conclusions |
T17 | 1471-1564 | Sentence | denotes | Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. |
T18 | 1565-1692 | Sentence | denotes | For children with severe or critical disease, this guidance offers an approach for decision-making regarding use of remdesivir. |